^
    1d
    Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New P2/3 trial
    |
    Reblozyl (luspatercept-aamt)
    2d
    A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 10
    Enrollment closed • Enrollment change
    |
    Reblozyl (luspatercept-aamt)
    8d
    A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Bristol-Myers Squibb | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date • Real-world evidence
    |
    Reblozyl (luspatercept-aamt)
    22d
    Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China (clinicaltrials.gov)
    P=N/A, N=88, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
    Trial completion • Trial completion date • Trial primary completion date • HEOR • Real-world evidence
    |
    Reblozyl (luspatercept-aamt)
    1m
    Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors. (PubMed, Expert Opin Pharmacother)
    Unmet needs include standardized endpoints, biologically stratified trials, and validation of hemoglobin and transfusion responses as markers. Strategies like momelotinib plus luspatercept, earlier intervention, and new molecular therapies could turn treatment from palliation to durable control and disease modification.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Xpovio (selinexor) • Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib) • pelabresib (DAK539) • elritercept (KER-050)
    1m
    A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions (clinicaltrials.gov)
    P2, N=30, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion
    |
    Reblozyl (luspatercept-aamt)
    1m
    Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=70 --> 6
    Enrollment closed • Enrollment change
    |
    SF3B1 (Splicing Factor 3b Subunit 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    SF3B1 mutation • SRSF2 mutation
    |
    Reblozyl (luspatercept-aamt)
    1m
    ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (clinicaltrials.gov)
    P3, N=360, Recruiting, Bristol-Myers Squibb | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Reblozyl (luspatercept-aamt)
    2ms
    Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis (clinicaltrials.gov)
    P2/3, N=196, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New P2/3 trial
    |
    Reblozyl (luspatercept-aamt)
    2ms
    ODYSSEY: Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (clinicaltrials.gov)
    P2, N=68, Recruiting, GlaxoSmithKline | Trial completion date: Nov 2026 --> Mar 2028 | Trial primary completion date: Oct 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib)
    2ms
    ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (clinicaltrials.gov)
    P3, N=360, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Reblozyl (luspatercept-aamt)
    2ms
    A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (PubMed, Leuk Lymphoma)
    Lower-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are commonly managed with erythropoiesis-stimulating agents, luspatercept, or hypomethylating agents. There were no dose-limiting toxicities. Although safe, fostamatinib demonstrated no clinical benefit, underscoring the need for alternative strategies to modulate inflammatory signaling in MDS/CMML.
    P1 data • Journal
    |
    SYK (Spleen tyrosine kinase)
    |
    Reblozyl (luspatercept-aamt) • Tavalisse (fostamatinib)